BA
TTNP

BlackRock Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

BlackRock Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$40K Hold
3
– – ﹤0.01% 3308
2016
Q3 		$66K Buy
3
+1
+50% +$19.4K ﹤0.01% 3172
2016
Q2 		$37K Buy
+2
New +$42.6K ﹤0.01% 3301
2016
Q1 		– Hold
0
– – – 3627
2015
Q4 		– Hold
0
– – – 3696

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock Advisors's TTNP Position: Q4 2016 in Review

BlackRock Advisors held its Titan Pharmaceuticals (TTNP) position steady in Q4 2016 at 3 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #3308.

BlackRock Advisors first reported a position in TTNP in Q2 2016 and has held it in 3 quarters since. The position peaked at $66K in Q3 2016. 47 funds tracked by Wall St. Rank hold TTNP as of Q4 2016.

  • BlackRock Advisors held 3 shares of Titan Pharmaceuticals worth $40K as of Q4 2016.
  • BlackRock Advisors left its Titan Pharmaceuticals share count unchanged in Q4 2016.
  • Titan Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3308 holding.
  • BlackRock Advisors first reported a position in Titan Pharmaceuticals in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Advisors's Titan Pharmaceuticals position peaked at $66K in Q3 2016.
  • 47 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.